Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2017-04-18 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Section 708A Notice 1 page 40.3KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX release dated April 19, 2017, from Imugene Limited. It announces the issue of 83,333,334 ordinary fully paid shares at a specified price pursuant to the partial underwriting of options. The notice references compliance with sections of the Corporations Act 2001 (Cth), specifically section 708A related to on-sale cleansing notices. The document is short (1897 characters) and serves as a formal announcement of a share issue without disclosure under certain regulatory exemptions. It does not contain financial statements or detailed financial analysis but rather a regulatory compliance notice about the share issuance. Therefore, it fits the category of Share Issue/Capital Change announcements rather than a full financial report or other categories.
2017-04-18 English
Appendix 3B (Exercise of Options) 12 pages 285.8KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is an official form used for announcing new issues of securities, application for quotation of additional securities, and related agreements. It contains detailed information about the class and number of securities issued, issue price, shareholder approvals, and quotation agreements with the ASX (Australian Securities Exchange). The content is regulatory in nature, focused on capital raising and securities issuance rather than financial performance or management commentary. It does not contain financial statements or earnings data, nor is it a report or presentation. This type of document is specifically used to announce capital raising activities and changes in the capital structure of the company. Therefore, it fits the category of 'Capital/Financing Update' (CAP). The document length is substantial (15,000 characters), indicating it is not a mere announcement of a report but a detailed filing about securities issuance.
2017-04-05 English
IMU Raises $3.0m from Options Plan 1 page 34.5KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated April 6, 2017, from Imugene Limited regarding the raising of approximately $3.0 million through the exercise of options under the company's option plan. It details the number of options exercised, the price per share, and mentions the issuance of unlisted options to a director subject to shareholder approval. The content focuses on financing activities related to the company's capital structure, specifically the exercise of options and issuance of new options. There are no financial statements, quarterly or annual results, or detailed management discussion. The document length is 3590 characters, which is relatively short and consistent with a capital/financing update rather than a full report. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-04-05 English
$1.35 million Options Underwritten 1 page 68.9KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated March 30, 2017, from Imugene Limited regarding underwriting agreements for $1.35 million AUD of options under the company's option plan. It details the underwriting fee, the underwriters involved, and the intended use of funds. The content focuses on a financing activity related to options underwriting and does not contain financial statements or detailed financial results. The document length is 2837 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is a full financial report, earnings release, or regulatory filing beyond the announcement of a capital raising event. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2017-03-29 English
Appendix 3B (Exercise of Options) 12 pages 296.3KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and agreements. It details the number and class of securities issued or to be issued, terms of securities, issue price, purpose of the issue, and compliance with ASX rules such as rule 7.1 and 7.1A. The document includes detailed information about share issues, options, and placement capacity calculations. It is not a financial report, earnings release, or management discussion but rather a regulatory announcement about capital raising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and detail confirm it is not a brief announcement or a report publication notice, but a substantive filing about capital changes.
2017-03-26 English
Imugene March Newsletter 5 pages 1.4MB
Investor Presentation Classification · 90% confidence The document is an investor newsletter dated March 2017, providing updates on company activities, scientific progress, patent filings, media coverage, and upcoming options offer deadlines. It is addressed to shareholders and includes business and scientific updates but does not contain formal financial statements, regulatory filings, or detailed financial results. It is a communication piece aimed at informing investors about ongoing developments and company news rather than a formal financial report or regulatory filing. Therefore, it fits best into the category of Investor Presentation (IP), as it focuses on company strategy, progress, and market positioning for investors.
2017-03-13 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.